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Hypertrophic fractional laser and keloid scars present a 
spectrum of disorders that are difficult to treat. Multiple 
treatments have been tried, to ameliorate the clinical 
sequelae of scarring, such as erythema, pruritus, func-
tional limitation, reduced range of movement, dyschro-
mias, hyper and/or hypopigmentation. Early international 
clinical recommendations on scar management first rec-
ognized the importance of laser therapy in this armamen-
tarium [1]. Within the years that followed, laser technology 
and the understanding of how it modulates the underly-
ing processes that leads to hypertrophic and keloid scar-
ring have experienced a quantum leap [2] and are still 
evolving. Lasers also present a considerable financial 
commitent, and it is possible, in the authors’ experience, 
that limited early results partially stemmed from limited 
availability of multiple lasers with consequent attempts to 
overstretch the indications for what was available.
This chapter presents a state-of-the-art insight into 
the use of fractional laser for the management of this 
complex problem. In particular, we focus on the man-
agement of complex scars such as those occurring post- 
burn injury and split-thickness skin grafting.
33.2  Method of Action
Light energy can be used to modulate or ablate specific 
targets in the skin through selective absorption of energy 
and specific heat energy dissipation properties [3]. The 
theory of selective photothermolysis, first described in 
1983, laid the foundations for subsequent developments 
and standard practices [3]. When used to induce a con-
trolled thermal injury, lasers initiate information pro-
cesses to increase vascular permeability and modulate 
matrix metalloproteinase production of collagen fiber 
deposition and tissue hypoxia caused by targeted vascu-
lar ablation [4]. Through these processes, wound healing 
specifically in the remodeling phase may be manipulated, 
resulting in scar maturation and obviation of symptoms 
[5]. Different types of lasers are useful in targeting the 
different components of this disease scar tissue and it is 
important that the laser practitioner has the essential 
range of appropriately powered tools required to pro-
duce an optimal effect.
The choice of fractional laser in the management of 
a hypertrophic spectrum scar depends upon whether an 
ablative or non-ablative effect is desired, the target chro-
mophore, the background skin type, the thickness of 
scarring, requirement for laser-assisted drug delivery 
(LADD), and the patient’s compliance with postopera-
tive downtime and regimes. The Azzopardi classification 
of chromophores also helps the practitioner rationalize 
the likely target and downstream metabolic effects [6]. 
Fractionated lasers with established effectiveness include 
CO2 and Er YAG (nanosecond modality). More recently, 
fractioned, picosecond Nd: YAG has emerged as a 
potent platform in this context.
33.3  Fractioned Laser Platforms
Fraction laser resurfacing creates microscopic columns 
of ablation in epidermis and dermis, termed microscopic 
treatment zones. The relationship of these zones to 
intervening blocks of normal tissue permit rapid heat 
dissipation yet deliver enough energy to allow immedi-
ate changes in scar pliability, and instigate scar remodel-
ing and neocollagenesis. The use of non-fractioned 
platforms such as pulsed dye and KTP (532 nm) are well 
documented and discussed elsewhere.
Fractioned CO2 (10,600 nm) and Er:YAG (2940 nm) 
are the two main ablative modalities in use, targeting 
water and collagen to produce mass transfer zones 
(MTZs) of defined diameter (70–100 μm) and depth, tis-
sue vaporization, and coagulation.
At the molecular level, fractional ablative laser 
treatment induces upregulation of  heat shock protein, 
upregulation of  matrix metalloproteinase, fibroblast 
apoptosis, downregulation of  transforming growth 
factors and basic fibroblast growth factors, and modu-
lation of  collagen-type ratios. These changes are evi-
dent beyond the microscopic treatment zones, yet the 
spared tissues contribute to rapid, normalized wound 
healing. A major difference however between CO2 and 
Er:YAG laser is the potential to achieve immediate 
coagulation and hemostasis: CO2 laser is 10 times 
more effective in this regard. This is critically impor-
tant when considering resurfacing of  extensive areas 
and when considering LADD, as in our experience, 
bleeding results in plugging and reduced LADD effi-
cacy. Moreover, the waveform characteristics of  a CO2 
laser have a significant bearing on the potential for 
side effects.
33.4  Fractioned CO2 Laser
Indications and timing: The latest version of  consen-
sus international guidelines for prevention and treat-
ment of  pathological scarring (2014) reserve the use of 
fractional laser therapy for scars refractory to pulsed 
dye laser; widespread hypertrophic burn scars that 
failed to improve with treatment with silicone gel or 
sheeting, pressure garments, and/or onion extract 
preparations for 8–12 weeks; minor keloids that failed 
to improve within 8–12 weeks with silicone gel sheet-
ing and intralesional corticosteroids; and major 
keloids resistant to improvement with intralesional 
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corticosteroids and 5-FU may be treated with ablative 
fractional laser or PDL therapy. This philosophy has 
been challenged by recent literature.
First, the use of  fractioned CO2 has since been suc-
cessfully used (to date, off-license) with extensive and 
well-documented success, as an adjunct facilitating 
transdermal delivery (see below) [7]. Pulsed dye is less 
effective in scars more than 1.2 mm depth, and do not 
allow for effective scar pliability that may substantially 
facilitate post-procedure physical therapy. From a 
basic sciences perspective, once it has been established 
that fractioned ablative laser may re-instigate appro-
priate scar remodeling, it would be more useful to tar-
get the scar during the remodeling phase once 
epidermal integrity is well established. Recent litera-
ture supports earlier intervention than the previous 6 
months to a year postinjury dogma, in concordance 
with our experience. In our experience, a treatment 
interval of  4–6 weeks is acceptable. Further, given the 
tendency of  corticosteroid to exacerbate telangiecta-
sias, use of  fractioned CO2 first (±LADD) followed by 
vascular-type laser to correct any resulting telangiec-
tasia may also be an acceptable and more time-efficient 
approach.
33.5  Settings for Ablative Fractional CO2 
Laser
Utmost caution is advised when deciding clinical set-
tings as these will vary between platforms. Many super-
pulsed lasers can only produce a shark tooth–type 
waveform. This results in the need to impart substan-
tially more energy for the therapeutic threshold to be 
achieved. This additional energy may be responsible for 
the increased risk of complications seen in the literature 
(both medical and legal) with these laser platforms. In 
contrast, lasers imparting a “top hat pattern” waveform 
impart only enough energy for the therapeutic threshold 
to be achieved. Further safety considerations include 
maintaining an inverse ratio of power to density, and 
ideally to avoid imparting a fluence that is above TRT, 
density sets the number of MTZs per unit area, which 
should not be above 10%. Ideally, for purposes of safety, 
pre- and post-cooling regime should also be considered. 
A cold-air blower provides excellent pre-and post- 
cooling as well as being an effective analgesic.
Further settings include the size, shape, pulse 
stacking, and depth. Shape and size of  the fractioned 
beam can be changed according to prevailing need. 
Whether the beam should penetrate beyond the scar 
thickness is still being investigated; however, injuries 
beyond the dermis may well lead to scarring and 
should be avoided [8].
33.6  Fractioned Erbium:YAG
The clinical efficacy of Er:YAG in keloid scars is lim-
ited. Cavale et  al. combined Er:YAG with twice daily 
topical  betamethasone under occlusion until therapeu-
tic maximum was achieved, resulting in 50% improve-
ment (median, n = 70), but recurrences also occurred in 
22% of lesions [9]. One factor which may explain this 
disappointing result is the limited ability of current 
Er:YAG technology to penetrated deeply, and lower 
hemostasis.
33.7  Fractional Non-ablative Laser
Fractional 1550 nm Erbium-doped fiber laser reported 
overall improvement in scar texture after four treat-
ments spaced 2  weeks apart, compared to the non- 
treated part of this split-scar study [10]. Literature 
reports that the response is mediated by heat shock pro-
tein, fibroblast proliferation, and consequent neocolla-
genesis [10].
A recent comparative RCT reports 1550  nm Er- 
doped fiber (70  mJ/23% coverage) to be superior to 
pulsed dye laser (7.5  mJ/10  mm/0.45  ms), with a 75% 
compared to 53% improvement reported [11, 12].
33.8  Picosecond, Fractioned, 1064 nm 
Nd:YAG
Management of hypertrophic and keloid scarring in 
darker skin types is a formidable challenge. Longer wave-
lengths, cooling devices, and lower treatment fluences 
have been shown to minimize complications [13, 14]. 
Recently, fractional picosecond 1064 lasers have reported 
good outcomes with very few side effects [15]. Compared 
to the conventional nanosecond domain QS Nd:YAG 
laser, the ps-Nd:YAG can produce significantly higher 
peak powers at the same energy level [16]. It is therefore 
expected that such technology works  principally through 
photomechanical rather than photothermal effects [17]. 
The inhibitory effect of the 1064-nm Nd:YAG laser 
against dermal collagen formation is documented in the 
literature [18–20]. More recently, the use of fractioned 
755 nm picosecond laser has been reported to be effective 
and safe in patients with Fitzpatrick skin types 4–6 [20].
33.9  Cautions and Contraindications
Caution is advised with any underlying process that 
impedes wound healing. History of herpes simplex virus, 
especially if  lasering is to be attempted in the peroral 
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area, should prompt prophylactic management. Oral 
antivirals or more recently bromelain should be consid-
ered [12, 21, 22]. Current depth of penetration for abla-
tive fractional devices is approximately 4  mm, and 
therefore management of deeper scars is less likely to be 
as effective [22].
33.10  Preoperative and Postoperative 
Regimes
No consensus exists with regard to preoperative prepa-
ration. Some prepare skin with chlorhexidine solution 
and moistening hair-bearing areas prior to treatment 
[23]. Others, including the authors, are content with 
cleansed, dry skin [24]. It is important to note that what-
ever preparation method is favored, that moist and 
humid surfaces result in reduced ablation, and increased 
heat latency since the primary target, water, is now in 
increased abundance.
Several factors influence the choice of  anesthesia, 
depending on the age of  the patients, available equip-
ment, and extent of  surface area treated. However, 
overarching principles governing the practice of  both 
authors include the use of  the safest, least-invasive 
modality first, pre-optimization, and dual effect of  skin 
cooling in increasing safety as well as providing an anal-
gesic effect. Within this context, pretreatment with top-
ical anesthetics of  increasing strength coupled with 
cold-air blowers may provide the mainstay of  analgesia 
requirements [25].
Where general anesthesia is required, it is possible 
to apply topical anesthesia immediately after fractioned 
CO2 lasering. However, the facilitation of  transdermal 
delivery will facilitate increased absorption (see below), 
and therefore it important to consider the maximum 
safe dose to avoid anesthesia-related toxicity. Use of 
ice- water packs immediately following treatment pro-
vides additional modalities for heat dissipation and 
analgesia [26].
Again, postoperative regimes vary widely, depending 
on resource, patient compliance, and experience. Use of 
antiseptic moisturizers, followed by a regime of moistur-
ization is strongly advised, along with hydrocortisone 
for pruritus. Sun protection is mandatory. Patients may 
resume normal activity almost immediately, including 
physical or occupational therapy. Showering is permit-
ted, with the exception of full immersion in standing 
(bath) water where ablative laser has been used. Some 
degree of edema is expected. Depending on the patient’s 
tolerance, compressive garments may be worn immedi-
ately after, but they may cause shear of treated tissue, 
and therefore it is sensible to recommend waiting for 
24–48 h before use.
33.11  Expected Outcomes
Benefits associated with CO2 laser treatment include 
increased scar pliability and reduced tightness, but it is 
important to impress on the patient that laser treatment 
creates the potential for increased scar pliability which is 
accomplished only by compliance with aggressive physi-
cal therapy postoperatively. Appropriate patient selec-
tion is therefore paramount, as is the availability of 
experienced and motivating physical therapists. Further 
benefits include reduced scar height and thickness. 
Pruritus has been observed to decrease in several studies 
presumably because nerve endings are no longer encased 
in tight scar tissues.
Similarly, fractioned CO2 laser may directly address 
the source of keloid formation, when this occurs in hair- 
bearing skin. Here, the hair follicle is encapsulated in the 
scar, which subsequently inflames, infects, and results in 
perpetuation of the insult-driving keloid growth. Scar 
remodeling results in amelioration of pliability, and in 
the authors’ experience it is not uncommon to result in 
resolution of the insult-driving keloidal growth as well 
as regrowth of hair in the site.
By inversely relating density to energy settings, it is 
also possible to attenuate relative scar height, resulting 
in flattening.
33.12  Potential Complications
The principal complications reported in the literature 
include burns, infection (viral, bacterial, mycotic) 
postoperative pain, and abnormal pigmentation: 
Post- inflammatory hyperpigmentation as well as 
hypopigmentation have been reported. In those being 
treated for burn injury memory flashbacks to the 
original incident have been reported in the literature, 
therefore it is essential that patients are forewarned. 
It is of  course important to discuss the potential of 
multiple treatments. A large prospective study per-
formed by Hultmann and colleagues puts the overall 
complication rate at 3.9% of  all treatments: in 
decreasing order of  incidence, hypopigmentation, 
blistering, hyperpigmentation, infection, cellulitis of 
the adjacent skin, superficial mycoses, and oral her-
pes simplex [27].
Practical recommendations for improving patient 
safety are judicious use of fluence (especially in darker 
skin types), use of pre- and post-cooling regimes, single 
pass, and avoiding stacking pulses, intentionally or oth-
erwise [8]. Multimodality treatment to one area within 
the same sitting is indeed possible, given the mastery of 
the underlying principles, correct understanding of the 
disease extent, the background skin type, and the 
patient’s potential for healing. However, it significantly 
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increases the risk for adverse events and therefore best 
avoided, except where mandated by individual risk–ben-
efit considerations and availability of experts with 
appropriate experience. The use of test-patching and ini-
tiation of treatment in non-cosmetically conspicuous 
areas are advocated. In addition, a readily available 
database of previous patient-specific settings allows set-
ting optimization to be delivered based on previous suc-
cesses or complications.
33.13  Fractioned CO2 Laser as a Method 
for Potentiating Transdermal 
Laser-Assisted Drug Delivery (LADD)
Ablative fractional laser breaches epidermal integrity, 
producing newly formed, uniform, and deep channels 
into hard dermal scars. It is well established (but at time 
of publishing as yet off  license) to harness this phenom-
enon as an effective method for trans-dermal drug deliv-
ery (. Fig.  33.1). The two-fold advantages may be 
summarized as follows: less pain and more even distri-
bution. First, traditional injection of volume into tight 
dermal scarring produces uneven distribution, creating 
blebs of volume while no treatment to adjacent areas. 
Volume injection into a tight scar also increases pain 
and discomfort [28]. Recent literature also points to var-
ious aspect of improvement this technique addresses, 
including pain tolerance, texture, dyschromia, and 
hypertrophy [26, 28, 29].
Pain relief: Intra-scar injection is often poorly toler-
ated pain-wise, especially when larger surface areas are 
being considered. Several studies have established that 
fractional Er:YAG pretreatment reduces up to twelve-
fold the time required for topical anesthesia to take 
effect. However, within these studies, it is impossible to 
assess whether mild adverse events reported (including 
residual pain, redness, or mild-moderate swelling) was 
due to the needle or laser, as the effect was measured 
only after the needle was inserted. Typical settings for 
this indication are fluence of 250 mJ/pulse, a pulse width 
of 300 microseconds, and an estimated pore depth of 
less than 20 mm [30–32].
More importantly, this data demonstrates that 
application of  local anesthesia post-procedure is likely 
to be more efficiently absorbed. While care needs to be 
taken with maximum dose due to altered absorption, 
post- procedure topical anesthesia may provide valu-
able pain relief, and is the standard practice of  one of 
the authors (EA) when treating larger areas of  sheet 
hypertrophic scarring post burns, with no side effects 
noted to date.
LADD has been used to potentiate transdermal 
delivery of  both corticosteroid [33–37] as well as 
5- fluorouracil [38] as well as combination treatment 
[38]. More recent evidence suggests that both are 
equally effective, but 5-FU does not lead to dermal 
atrophy or telangiectasia seen with corticosteroid 
delivery [39].
33.14  Consensus Practice
Established clinical consensus is that ablative lasers are 
significantly more effective per treatment for scar 
improvement than their non-ablative counterparts, 
especially for keloid and hypertrophic contracted scars, 
with significant gain in pruritus, pain, and physical 
mobility within days and up to 2 weeks posttreatment. 
Usually, rapid improvement in dyspigmentation is fol-






  . Fig. 33.1 In Laser Assisted 
Drug Delivery, is a recent 
advancement where laser energy 
is used to enhance trans-dermal 
drug delivery. For scarring a, 
typically, a fractioned ablative 
laser beam is used to create 
channels within the scar b. This 
is followed expeditiously with 
topical application c. The topical 
application is massaged in to the 
lasered area to enhance 
absorbtion d
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